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Abstract
Delta-Like 1 Homolog, Dlk1, is a paternally imprinted gene encoding a transmembrane protein involved in the
differentiation of several cell types. After birth, Dlk1 expression decreases substantially in all tissues except endocrine glands.
Dlk1 deletion in mice results in pre-natal and post-natal growth deficiency, mild obesity, facial abnormalities, and abnormal
skeletal development, suggesting involvement of Dlk1 in perinatal survival, normal growth and homeostasis of fat
deposition. A neuroendocrine function has also been suggested for DLK1 but never characterised. To evaluate the
neuroendocrine function of DLK1, we first characterised Dlk1 expression in mouse hypothalamus and then studied post-
natal variations of the hypothalamic expression. Western Blot analysis of adult mouse hypothalamus protein extracts
showed that Dlk1 was expressed almost exclusively as a soluble protein produced by cleavage of the extracellular domain.
Immunohistochemistry showed neuronal DLK1 expression in the suprachiasmatic (SCN), supraoptic (SON), paraventricular
(PVN), arcuate (ARC), dorsomedial (DMN) and lateral hypothalamic (LH) nuclei. DLK1 was expressed in the dendrites and
perikarya of arginine-vasopressin neurons in PVN, SCN and SON and in oxytocin neurons in PVN and SON. These findings
suggest a role for DLK1 in the post-natal development of hypothalamic functions, most notably those regulated by the
arginine-vasopressin and oxytocin systems.
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Introduction
Delta-Like 1 Homolog (DLK1), also known as preadipocyte
factor 1 (Pref-1), is a transmembrane protein expressed at the cell
surface. It comprises an extracellular domain containing epidermal
growth factor (EGF)-like repeats, a transmembrane domain, and a
short intracellular tail. DLK1 is encoded by a paternally imprinted
gene located on chromosome 12 in mouse and chromosome 14 in
human. In mouse, Dlk1 is widely expressed in embryonic tissues,
and its expression level decreases markedly after birth except in a
few endocrine glands and a subset of dopaminergic neurons [1–3].
The protein shares structural characteristics with the Notch/
Delta/Serrate family but lacks the DSL (Delta/Serrate/LAG-2)
domain conserved in all classic Notch ligands [4]. Soluble DLK1 is
generated by shedding from the transmembrane domain of the
extracellular domain cleaved by the ADAM17/TACE enzyme [5–
8].
In recent years, evidence has accumulated that DLK1 inhibits
adipocyte differentiation [8,9]. It is also involved in other
biological processes such as determination of the fate of many
cell types including pancreatic islet cells [10], myocytes [11],
hepatocytes [12] and neurons [13]. In adults, Dlk1 is expressed in
the normal pituitary gland, spinal cord, pancreatic islet cells,
adrenals, and leydig cells, strongly suggesting a role in endocrine-
related functions. DLK1 has been demonstrated to suppress
growth hormone expression in GH3 cells [14].
Mice lacking paternally expressed Dlk1 display pre- and post-
natal growth deficiency, obesity, facial abnormalities, and
abnormal skeletal development. This phenotype is not observed
after maternal transmission of the null allele [15]. Mice with
double or triple doses of Dlk1 display embryonic growth
enhancement followed by a failure to thrive and peri-natal
lethality [16]. These phenotypes resemble those seen in maternal
or paternal unidisomy of chromosome 12 [16]. A similar
phenotype associated with precocious puberty has been reported
in patients with maternal uniparental disomy of the orthologous
region of chromosome 14 (14q32) and potentially ascribed to
absence of Dlk1 expression [17].
Although there is some evidence that DLK1 may exert
neuroendocrine effects [18–20], the hypothalamic functions of
DLK1 have not been evaluated. The objective of this study was to
characterize Dlk1 expression in the mouse hypothalamus after
birth in order to clarify the potential neuroendocrine function of
DLK1. For that purpose, hypothalamic and pituitary DLK1
expression was analyzed, hypothalamic nuclei and neurons
expressing DLK1 were characterized in adult mice and post-natal
variations in hypothalamic Dlk1 expression were quantified.
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Mice
Wild-type Swiss mice were supplied by Janvier (Le Genest Saint
Isle, France) and housed in cages with free access to food and tap
water, a 12-h light-dark cycle (8:00 AM/8:00 PM) and constant
temperature (21uC). Full details of the study have been approved
by the Robert Debre ´ research council review board; the approval
number is 2010-13/676-008. All experiments were carried out in
compliance with the ethical rules of our institution (National
Institute for Health and Medical Research, INSERM) and with
the recommendations in the National Research Council’s Guide
for the Care and Use of Laboratory Animals. Experiments were
conducted in male mice on post-natal day P6 (neonates), P20
(juveniles), and P60 (adults).
Tissue dissection
On the day of sacrifice, the mice were weighed, anaesthetized
with inhaled isoflurane, and killed by decapitation. The brains
were removed and the hypothalami and pituitaries were dissected
and frozen in isopentane dry ice at 240uC then stored at 280uC
until RNA extraction. To assess possible changes in hypothalamic
gene expression associated with puberty in male mice, animals
were killed at three different stages of development (P6, P20, and
P60).
Immunohistochemistry
Tissue preparation. The mice were deeply anaesthetized
with isoflurane and perfused intracardially for 2 to 5 min with 4%
paraformaldehyde in 0.12 M phosphate buffer (PB), pH 7.4. After
the perfusion, the brain was immediately removed and maintained
in the same paraformaldehyde solution for approximately 3 hours,
at 4uC. All specimens were then cryoprotected in 15% sucrose/PB
for 24 hours at 4uC then in 30% sucrose/PB for 24 hours at 4uC,
for preparation of 30-mm free-floating sections. The brains were
frozen in liquid isopentane at 270uC and stored at 280uC until
sectioning. Coronal sections 30 mm in thickness were cut on a
cryostat and collected in PB.
Immunohistochemistry. For fluorescent staining, free-
floating slices were incubated with 5% donkey serum in 0.3%
Triton X-100 phosphate buffered saline (PBS) for 45 minutes, to
block non-specific antibody reactions. The slices were then
incubated overnight with primary antibodies at 4uCi n1 %
donkey serum in 0.3% Triton X-100 PBS. After several rinses with
PBS, the slices were incubated with a secondary fluorescent
antibody in 1% donkey serum in 0.3% Triton X-100 PBS for
2 hours at room temperature. After three washes in PBS, the
sections were stained with TO-PRO-3 (1/500, Invitrogen), rinsed
in PBS, collected on Superfrost Plus slides (Microm Microtech,
Francheville, France), and covered with fluoromount
(Southernbiotech, Birmingham, AL, USA) for fluorescence
microscopy.
For peroxidase staining, free-floating slices were incubated with
5% donkey serum in 0.3% Triton PBS for 1 hour, then with
primary antibody in 1% donkey serum in 0.3% Triton PBS
overnight at 4uC. After several washes with PBS, the slices were
incubated with the secondary biotinylated antibody in 1% donkey
serum in 0.3% Triton PBS for 90 minutes at room temperature.
After incubation with H2O2 0.3% in PBS for 10 minutes, the slices
were rinsed and the universal immunolabelling system streptavi-
din-peroxidase kit (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, USA) was used to develop the reaction. Cresyl
violet 1% was used to counterstain nuclei of the brain sections, and
the slides were then mounted with Pertex resin.
Controls for double-labeling included omission of the primary
antibodies to test for non-specific binding of the secondary
antibodies and incubation with one primary but both secondary
antibodies to demonstrate the absence of cross labeling. Specificity
for DLK1 immunostaining was tested by immunoadsorption of the
antibody (1 mg/ml) with 10 mg/ml of DLK1 peptide for
60 minutes at room temperature followed by centrifugation at
4uC for 10 minutes at 15 000 g. The supernatant was then used
for immunochemistry as described above.
The images were acquired using a Zeiss Axio Observer inverted
microscope equipped with an LSM 5 Exciter confocal scanning
system (Carl Zeiss, Jena, Germany). Excitation and emission filters
were as follows: Cy3, lex=548 nm and lem=560/600 nm; TO-
PRO-3, lex=633 nm and lem=650/695 nm; and Alexa 488,
lex=488 nm and lem=505/545 nm. The level of each coronal
section from the bregma was determined according to the mouse
brain atlas [21].
Antibody characterization. Specific information on
company, immunogen and antigen specificity of the antibodies
used in this study can be found below.
The goat polyclonal C-19 and the rabbit polyclonal H-118
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
were raised against a C-terminal peptide or a fragment
corresponding to amino acids 266–383 of the human DLK1
respectively. The 266–383 region of the human DLK1 comprises
the C-terminal end of the extracellular domain (37 residues)
including one proteolytic site, the transmembrane domain and the
entire intracellular domain. The specificity of C-19 and H-118 has
been previously established in immunoblot of liver extracts by
showing a band at the expected size for the full length DLK1 [22].
In addition, immunostaining with the C-19 has been completely
blocked by preadsorption with the DLK1 antigenic peptide (sc-
8624p, Santa Cruz Biotechnology, see results below). The H-118
antibody staining matched the C-19 antibody (see results) and the
mapping of Dlk1 mRNA expression in mouse brain (Allen Institute
Brain Atlas) [21].
Two antibodies against the microtubule-associated protein 2
(MAP2A-2B) and SMI-31 were used to determine the subcellular
location of DLK1. The monoclonal MAP-2 mouse antiserum
(Chemicon Millipore, Temecula, CA; MAB3418) was prepared
against the bovine brain microtubule protein, recognizing a double
band (corresponding to MAP-2a and MAP-2b) of 300 kDa
(manufacturer’s technical information). This antibody labeled the
normal somato-dendritic distribution of MAP-2 in adult rodent
neurons [23]. The mouse monoclonal antibody anti-SMI-31
raised against phosphorylated neurofilament (Sternberger mono-
clonals, Covance, San Diego, CA) was originally raised against rat
hypothalamus proteins [24] and was demonstrated to label
phosphorylated neurofilament in rat brainstem [25]. Jones et al
have previously reported its specificity in rodent brain study [26].
Several antibodies were used to determine DLK1-expressing
hypothalamic neurons. Specificities of these antibodies were
established by different methods. i) Vasopressin: the rabbit
polyclonal anti-vasopressin (Immunostar, Hudson, WI, USA)
was raised against synthetic arginine vasopressin (AVP) coupled
to bovine thyroglobulin. Previous studies have shown that
preadsorption with synthetic vasopressin peptide (10 mM) resulted
in a complete loss of immunolabeling in the paraventricular
nucleus of rodent hypothalamus [27]. ii) Oxytocin (OXT): the
rabbit polyclonal anti-oxytocin serum (Chemicon Millipore,
AB911) was produced against full-length oxytocin conjugated to
thyroglobulin. Specificity of the antibody and cross reactivity to
arginine vasopressin was established by immunoblot (Chemicon
information) and by preadsorbing the antisera using the synthetic
DLK1 Expression in the Post-Natal Hypothalamus
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beling [28]. iii) Vasoactive intestinal peptide (VIP): a polyclonal
antibody (INCSTAR, #20077) was raised against VIP conjugated
to bovine thyroglobulin with carbodiimide. The specificity of the
antibody has been previously established [29]. iv) Growth-
hormone-releasing hormone (GHRH): a polyclonal antibody (a
gift from C. Loudes, INSERM U894, Paris France) was raised in
rabbit against the 25-amino-acid C-terminal part of the mouse
GHRH sequence in which the 17-Tyr moiety was replaced by a
Cys to allow conjugation to keyhole limpet hemocyanin as carrier
[30]. The specificity of the antibody was established by the co-
staining of endogenous GHRH with eGFP fluorescence in
GHRH-eGFP transgenic mouse [30]. v) Neuropeptide Y (NPY):
the NPY antibody (a gift from E. Grouzmann, Lausanne,
Switzerland) is a mouse monoclonal antibody raised against the
neuropeptide NPY [31]. The specificity of this antibody has been
previously established in the hypothalamus [32]. vi) Alpha-
melanocyte-stimulating hormone (a-MSH): the sheep polyclonal
a-MSH antiserum was raised against a-MSH conjugated with
bovine thyroglobulin (Chemicon Millipore, #AB5087). The
specificity of the a-MSH antibody was established by the complete
absence of staining after pre-immunoadsorption with the immu-
nogenic peptide [33]. vii) Kisspeptin: this antibody was raised
against a synthetic mouse peptide Kp10 (A gift from Alain Caraty,
IFR 145, INRA, Nouzilly, France). Its specificity has been
established by the absence of staining after preimmunoadsorption
with the antigenic peptide [34] and in Kiss1 deleted mouse.
Additionally, no cross-reactivity with peptides of similar size and/
or known to be related peptides (e.g. prolactin-releasing peptide, a
peptide of the RFamide family) has been shown [35]. viii) Glial
fibrillary acidic protein (GFAP): the polyclonal rabbit antibody was
raised against GFAP isolated from bovine spinal cord (reference
Z0334, Dako, USA). The GFAP antibody recognizes the well-
known intermediate filament protein expressed by astrocytes, and
detects a band of 51 kDa on western blots of rodent brain extracts
[36]. The secondary antibodies were Cy3 donkey anti-goat
(Jackson, Suffolk, UK), Alexa 488 donkey anti-mouse (Invitrogen,
Carlsbad, CA, USA), Alexa 488 donkey anti-rabbit (Invitrogen),
peroxidase-conjugated AffinityPure donkey anti-rabbit IgG (Jack-
son), and peroxidase-conjugated donkey anti-goat IgG (Jackson).
Western blot analysis
Hypothalami and pituitaries from male mice were micro-
dissected, snap-frozen in liquid isopentane at 270uC and stored at
280uC until further analysis. Tissue was homogenised in RIPA
buffer (50 mM Tris-HCl pH 8, 0.1% SDS, 1% NP40, 150 mM
NaCl, 0.5%Na deoxycholate, 1 mM PMSF, and protease
inhibitors). For Western blot analysis of total protein extract,
tissues in lysis buffer were centrifuged at 25 000 g at 4uC for
15 minutes and the supernatant was collected and stored at 280u
until further use. For Western blot analysis of membrane protein
extract, tissues homogenised in lysis buffer (10 mM Tris-HCl
pH 7.4, 1 mM EDTA, protease inhibitor (Boehringer Mannheim,
Reims, France), and 1 mM PMSF) were centrifuged at 200 g at
4uC for 5 minutes and the supernatant was then centrifuged at
25 000 g at 4uC for 30 minutes. The supernatant containing the
cytoplasmic proteins (post-nuclear supernatant) was collected and
stored at 280u until further use. The pellet was solubilised in
50 mM Tris pH 6.8, 150 mM NaCl, 10% glycerol, and 1%
Triton, incubated for 60 minutes at 4uC on a wheel, and
centrifuged at 25 000 g for 15 min at 4uC. The supernatant was
collected and stored at 280uC. Protein concentrations were
determined using the BCA protein assay kit (Pierce, Rockford, IL,
USA). Protein extracts (20 mg per sample) were denatured with b-
mercaptoethanol and 56SDS Page in loading buffer at 96uC for
5 minutes. Proteins were separated on polyacrylamide gel (8% or
4–20% gradient gel) and transferred onto polyvinylidene difluoride
membranes (ProBlot, ABI, Foster City, CA, USA). The mem-
branes were rinsed with Tween 0.2% containing PBS, saturated
with blocking solution (3% donkey serum) for 1 hour at room
temperature, and incubated overnight at 4uC with primary
antibodies in PBS, 0.2% Tween 20, and 0.5% donkey serum.
After incubation with peroxidase-labelled secondary antibody,
enhanced chemiluminescence (Immun-Star WesternC, Biorad,
Marnes-la-Coquette, France) was used to detect the immunore-
active protein, (Chemidoc, Biorad, Marnes-la-Coquette, France).
Equal loading and transfer of samples were confirmed according
to the b–actin signal (mouse anti-ß-actin antibody from Sigma,
Saint Quentin Fallavier, Fr).
Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the hypothalamic and pituitary
tissues using Trizol, (Invitrogen). Reverse transcription into first-
strand cDNA of total RNA (800 ng) was achieved using random
primers and the SuperScriptH II Reverse Transcriptase Reagent
Kit (Invitrogen). PCR was performed to amplify cDNA in PCR
buffer (50 mM Tris pH 8, 50 mM KCl) with 0.2 mM of each
primer (table S1), 0.2 mM of dNTP and 1 mL of TAQ polymerase
(Redgoldstar, Eurogentec, Seraing, Be) for 35 cycles after initial
denaturation at 95uC for 5 min. The reaction products were
separated on 2% agarose gel and visualised using an ultraviolet
apparatus.
Quantitative polymerase chain reaction analysis
The ABI Prism 7300 HT Sequence Detection System (PE
Applied Biosystems, Foster City, CA, USA) was used to perform
real-time PCR (see table S1 for primer sequences). Each target was
amplified individually and in duplicate. Relative expression was
calculated using the comparative threshold cycle (CT) method. For
each quantitative PCR analysis, technical validation was per-
formed according to standard procedures. A dissociation curve
was plotted to check that a single amplicon was generated. The
size of each amplicon was assessed on agarose gel to confirm
primer specificity. PCR primers were validated when the slope
generated using different cDNA dilutions was between 22.9 and
23.3 and the correlation coefficient was between 0.95 and 1.
Statistical analysis
We computed the mean mRNA levels in the replicates for each
experimental repeat. Experimental groups were compared using
ANOVA (Turkey’s post hoc test). All data were described as mean
(6SEM). All statistical analyses were performed using GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA, USA).
Results
Two Dlk1 isoforms are expressed in the hypothalamus
and pituitary
To determine Dlk1 isoforms expressed in the hypothalamus and
pituitary, reverse transcribed total RNA was PCR amplified using
two primers located in exons 4 and 5 (see table S1). Two PCR
products of about 1000 bp and 800 bp were identified in both
tissues (Figure 1A). After gel purification, sequencing showed that
the two PCR products differed by a 225-bp deletion between
nucleotides 836 and 1062 (cDNA numbering). These two mRNA
isoforms have been described previously as isoform Dlk1-A, which
is translated into the full-length protein (DLK1-A) and isoform
Dlk1-C2 arising by differential splicing within exon 5, which
DLK1 Expression in the Post-Natal Hypothalamus
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expression of the two Dlk1 mRNA isoforms differed between the
hypothalamus and pituitary: Dlk1-A was expressed at a higher level
than Dlk1-C2 in the hypothalamus, whereas Dlk1-C2 predominat-
ed in the pituitary (Figure 1A).
DLK1-A and DLK1-C2 differed by 75 residues in the
juxtamembrane region (Figure 1B). A cleavage site has been
described in this juxtamembrane region of the extracellular
domain of DLK1-A but not DLK1-C2 [5]. In total protein
extracts from both the pituitary and the hypothalamus, an
antibody raised against the 266–383 region of human DLK1 (H-
118) which comprises part of the extra-cellular domain (24–303),
the transmembrane domain (304–327) and the intra-cellular
domain (328–383), detected three bands, of 52-kDa, 46-kDa and
30-kDa, respectively. The C-19 antibody directed against a C-
terminal peptide of the intracellular domain revealed very faint
bands at 46-kDa and at 52-kDa but no band at 30-kDa
(Figure 1C). We suspected that the 46-kDa and 52-kDa bands
corresponded to uncleaved glycosylated forms of DLK1 and that
the 30-kDa band corresponded to a soluble form of DLK1
probably cleaved from the DLK1-A. This DLK1soluble form was
missing the intracellular domain. To confirm this result, we
compared DLK1 protein isoforms from post-nuclear supernatants
to molecular forms solubilized from membrane extracts
(Figure 1D). 46- and 52-kDa bands were very intense in
membrane extracts of pituitary (Figure 1D) whereas the intensity
of these two bands was very low in membrane extracts of
hypothalamus (Figure 1D). The 30-kDa molecular form was found
in post-nuclear supernatants of both tissues but not in membrane
extracts (Figure 1D). In the pituitary, the 30-kDa band was less
intense than the 46- and 52-kDa bands. In contrast, the 30-kDa
band in the hypothalamus was almost the only visible band.
Both antibodies identified an additional band, of 12 kDa, in
pituitary membrane extracts (Figure 1D). We assumed that this 12-
kDa band corresponded to a protein fragment composed of parts
of the transmembrane and intracellular DLK1 domains.
Thus, DLK1 was expressed in pituitary and hypothalamic tissue
as an uncleaved transmembrane protein, and a soluble 30-kDa
isoform composed only of the extracellular domain. A small 12-
kDa transmembrane protein probably containing the intracellular
domain was only found in the pituitary. Pituitary tissue chiefly
expressed uncleaved DLK1, whereas the 30-kDa soluble DLK1
was the predominant form in adult hypothalamic tissue.
DLK1 is expressed in the arcuate, paraventricular,
supraoptic, suprachiasmatic, dorsomedial and lateral
hypothalamic nuclei
Immunohistochemistry (IHC) performed using the C-19
antibody showed intense labeling in the suprachiasmatic nucleus
Figure 1. DLK1 expression in the adult male mouse hypothalamus and pituitary as uncleaved and cleaved proteins. (A) Reverse-
transcription polymerase chain reaction (RT-PCR) was performed using two primers located in Dlk1 exons 4 and 5 as described in materials and
methods. (B) Schematic representation of the DLK1-A and C2 isoforms. The arrows indicate the proteolytic cleavage sites described by Smas et al. [5].
The dark grey boxes indicate epidermal growth factor (EGF)-like repeats. SP: signal peptide region. TMD: transmembrane domain. JMD:
juxtamembrane domain. ECD: extracellular domain. ICD: intracellular domain. (C) Western blot on total proteins extracted from adult male mouse
hypothalamus and pituitary. (D) Pituitary and hypothalamic DLK1 isoforms were characterized in post-nuclear supernatants (PNS) and membrane
extracts (M). DLK1 isoforms were detected using a goat polyclonal anti-DLK1 antibody against the intracellular domain (C-19) and a rabbit polyclonal
anti-DLK1 antibody against part of the extracellular domain, the transmembrane and the intracellular domain (H-118). NP, non-proteolysed DLK1.
doi:10.1371/journal.pone.0036134.g001
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supraoptic nucleus (SON), arcuate nucleus (ARC), dorsomedial
(DMN) and lateral hypothalamic nucleus (LH) (Figure 2). The
same staining was found with the H-118 antibody produced in
rabbit and directed against a region of the protein comprising
parts of extracellular and intracellular domains of DLK1 (data not
shown). The absence of staining after immunoabsorption of C-19
antibody by the DLK1 antigenic peptide as well as DLK1 staining
in somatotrophs in the anterior pituitary (figure S1A) show that C-
19 hypothalamic staining was specific [38]. Furthermore, this
DLK1 staining reproduced the pattern observed by in-situ
hybridization (http://mouse.brain-map.org/gene/show/13165).
Indeed with a probe against nucleotides 426 to 1229
(NM_010052), a signal was observed in the PVN, SCN, SON,
DMN and ARC of the mouse hypothalamus.
To specify the subcellular location of DLK1, we performed dual
IHC with antibodies against DLK1 and specific markers of
dendrites or axons. MAP-2 is involved in microtubule assembly
and is found in large amounts in dendrites. Double IHC with an
antibody raised against MAP-2 showed co-staining with DLK1 in
dendrites as well as in perikarya (Figure 3), whereas DLK1 was
never co-stained with SMI-31, a protein active primarily in the
distal portions of axons (Figure 3). No co-staining was found with
the glial fibrillary acidic protein (GFAP) (data not shown).
DLK1 thus emerged as a somatodendritic protein expressed in
neurons located in the PVN, SCN, SON, DMN, ARC and LH
nuclei.
Hypothalamic Dlk1 expression increases between birth
and adulthood
As persistent Dlk1 expression was found in the adult mouse
hypothalamus, it was of interest to analyse variations in
hypothalamic Dlk1 expression after birth. Significant increases in
Dlk1 mRNA were observed between P6 and P20 (2.4060.14-fold
increase (FI), n=4, p,0.01) and between P6 and P60 (2.8060.15
FI, n=4, p,0.01) (Figure 4A). These increases were similar to that
seen for Kiss1 expression (P6 vs. P20, 2.2060.27 FI; n=4, p,0.05;
P6 vs. P60, 2.660.46 FI; n=4, p,0.01) (Figure 4A), which was
recently described as a major determinant of pubertal onset
[39,40]. Western Blot analysis of total extracts of P6, P20, and P60
hypothalamic tissues from male mice showed that the 30-kDa
isoform levels increased from P6 to P20 and P60 (Figure 4B). The
post-natal increase in hypothalamic Dlk1 mRNA was therefore
associated with increased expression of the protein. DLK1 was
expressed in the same nuclei (ARC, PVN, SCN, DMN, SON and
LH) at all three post-natal time points (P6, P20, and P60) (see
figure S2), indicating that the post-natal increase in hypothalamic
DLK1 expression resulted from modulation of existing expression
and not from expression by additional hypothalamic nuclei.
Dlk1 is expressed in arginine-vasopressin and oxytocin
neurons
Our finding of DLK1 expression in the SCN, PVN and SON
suggested expression in neurons expressing vasoactive intestinal
peptide, arginine-vasopressin or oxytocin. Double IHC with the
C-19 antibody and a rabbit antibody against VIP revealed that
VIP-expressing neurons did not express DLK1 (data not shown).
Double IHC with an antibody against AVP or OXT showed
DLK1 expression in AVP and OXT neurons in the PVN
(Figure 5A). In this nucleus, very few AVP+ neurons do not
express DLK1 whereas in the LH, the majority of DLK1+ neurons
do not express AVP or OXT (data not shown). Co-immunostain-
ing between DLK1 and AVP was also observed in the SCN and as
expected, there were no OXT+ neurons in this nucleus (Figure 5B).
In the SON, AVP+ neurons express DLK1, but few DLK1+ fibers
were not stained for AVP (Figure 5C). In this nucleus, DLK1
immunostaining was observed in OXT+ perikarya and fibers
(Figure 5C). Double IHC with antibodies against GHRH, NPY, a-
MSH, and Kisspeptin showed no co-staining with DLK1 in the
ARC (data not shown). There was no evidence of DLK1
immunostaining in AVP axonal extremities in the neuronal lobe
of the pituitary (Figure S1B).
Altogether, these results indicated that AVP-expressing neurons
co-express DLK1 in the PVN, SCN, and SON. OXT-expressing
neurons co-express DLK1 in the PVN and the SON mostly in the
neurons fibers. Few DLK1-expressing neurons in the LH express
AVP or OXT.
Discussion
Very little is known about the biological function of Dlk1.
Expression of Dlk1 is found in many embryonic tissues but
decreases in several tissues after birth, an event that is critical to
various processes leading to cell differentiation [1,2]. A neuroen-
docrine function has been hypothesized for DLK1 but has never
been characterized. Our results show that DLK1 expression in the
hypothalamus occurs mainly as a cleaved protein and it is
expressed in dendrites of AVP and OXT neurons in the PVN and
LH nuclei. In the SON, DLK1 was co-stained mostly with AVP
and only with few OXT-expressing neurons. DLK1 expression
was also found in neurons negatives for AVP, OXT and other
neurons negatives for peptides expressed in the ARC nucleus such
Figure 2. DLK1 is expressed in specific nuclei of the hypothal-
amus. A) Immunohistochemistry using the C-19 antibody was
performed on free-floating coronal brain sections from adult male
mice as described in materials and methods (2,56 objective; Bregma
20.82 mm at the hypothalamic level according to the mouse brain
atlas [21]. B) Bregma 22.06 mm C) Higher magnification of the
paraventricular nucleus (PVN), suprachiasmatic nucleus (SCN), supraop-
tic nucleus (SON) arcuate nucleus (ARC), and lateral hypothalamic
nucleus (LH) (206objective; scale bar: 80 mm).
doi:10.1371/journal.pone.0036134.g002
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(C-19) and phosphorylated neurofilament (SMI-31) or microtubule-associated protein 2 (MAP-2) on free-floating sections of hypothalami from adult
male mice. Tissue was fixed and processed as described in materials and methods. Arrowheads indicate co-staining of DLK1 and MAP-2 in dendrites
and perykarya. DLK1 do not colocalize with SMI-31 (406objective for MAP-2 and 636objective for SMI-31, scale bar: 10 mm).
doi:10.1371/journal.pone.0036134.g003
Figure 4. Dlk1 expression increases in the hypothalamus between birth and adulthood. A) Total hypothalamic RNA was extracted on post-
natal days 6, 20 and 60 (P6, P20, P60). mRNA levels were quantified using real-time RT-PCR as described in the materials and methods section. The
graphs show fold increases in expression at P20 and P60 compared to P6. Kiss1 expression was quantified using real-time RT-PCR as described in the
materials and methods section. The graphs represent pooled data (mean 6 SEM) from three different experiments with 4 mice per group. *indicates
a significant increase (p,0.01) relative to P6. B) DLK1 protein levels on P6, P20 and P60 were evaluated using western blot on total cellular extracts
with the H-118 antibody.
doi:10.1371/journal.pone.0036134.g004
DLK1 Expression in the Post-Natal Hypothalamus
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36134as NPY, a–MSH, GHRH, Kisspeptin. The hypothalamic Dlk1
expression increases after birth suggesting that DLK1 expression is
associated with the post-natal maturation of hypothalamic
neurons.
DLK1-A and DLK1-C2 are transmembrane proteins of 385
and 310 amino acids with calculated molecular weights at 41-kDa
and 33-kDa, respectively. DLK1-A differs from the DLK1-C2 by
the presence of a sequence of 75 amino acids bearing a proteolytic
cleavage site. The mouse hypothalamus mainly expresses a soluble
30-kDa DLK1 protein fragment. This DLK1 protein fragment is
recognized by an antibody directed against the extracellular
domain but not by an antibody directed against the intracellular
domain of DLK1. From this information, we can hypothesize that
the 30-kDa protein fragment is a part of the extracellular domain
of DLK1. Furthermore, the mouse hypothalamus mainly expresses
the Dlk1-A mRNA isoform. From this, we propose that the
hypothalamic DLK1 is mainly expressed as a cleaved DLK1-A
isoform. However, the expression of DLK1 in the pituitary differs
from that of the hypothalamus. The pituitary expresses a high
amount of two 46-kDa and 52-kDa uncleaved DLK1 and low
amount of 30-kDa and 12-kDa DLK1 protein fragments.
Important, the pituitary expresses higher amount of Dlk1-C2
mRNA than Dlk1-A mRNA and Dlk1-C2 encodes for a protein
lacking the extracellular domain cleavage site present in DLK1-A.
We therefore propose that the 46- and 52-kDa DLK1 molecular
forms expressed in the pituitary are two different O- or N-
glycosylation states of the DLK1-C2 isoform. The difference
between DLK1 molecular weights found in our study and in
earlier studies [8] may reflect differences in the O- or N-
glycosylation status of the extracellular domain in neurons
compared to COS cells or fibroblasts [41]. Further analysis of
the glycosylation status of DLK1 is required to confirm this tissue-
specific post-translational modification. The 12-kDa-protein
fragment was found in pituitary but not in hypothalamic
membrane extracts. Therefore, this 12-kDa fragment is probably
cleaved from the DLK1-C2 isoform.
The hypothalamus mainly expressed cleaved DLK1, whereas
the pituitary expressed mainly uncleaved DLK1. A larger amount
of Dlk1-C2 mRNA than of Dlk1-A mRNA is expressed in the
pituitary, which contrasts with the marked predominance of Dlk1-
A mRNA in the hypothalamus. The DLK1-C2 isoform lacks the
juxtamembrane cleavage site recognized by the ADAM enzyme
involved in one of the cleavages of the DLK1 extracellular domain
[8]. Further work is needed to determine whether differences in
the relative expression levels of DLK1-A and DLK1-C2 between
the hypothalamus and pituitary may serve to regulate the ratio of
cleaved to uncleaved DLK1, and therefore the biochemical
function of this protein.
The high level of DLK1 expression in the SCN is striking and
co-staining was found with AVP expressing neurons. In the SON,
DLK1 is mainly expressed in AVP-expressing neurons. The co-
staining of DLK1 with MAP-2 and AVP or OXT-expressing
neurons was associated with the absence of DLK1 staining in the
neural lobe of the pituitary, where AVP and OXT axons
terminate. DLK1 is thus a somatodendritic protein of AVP- and
OXT-expressing neurons. AVP and OXT are two neuropeptides
secreted from two types of neurons, namely, the magnocellular
and parvocellular neurons. The AVP from magnocellular neurons
from the PVN and the SON acts as a neurohormone. It is
transported through the axon passes through the inner zone of the
median eminence, and reaches the nervous lobe of the pituitary
gland; it is then secreted into the circulation to modulate the
activity of certain organs such as kidney and therefore involved in
osmoregulation. Peripheral actions of OXT are to stimulate
uterine contraction and lactation.
Central dendritic release from magnocellular neurons have
been described for both AVP and OXT peptides [42]. Central
effects of both neuropeptides, AVP and OXT have been well
documented in the regulation of social behavior, circadian rhythm
as well as modulation of the hypothalamic-pituitary adrenals axis
in response to stress [42,43]. As dendritic arborescence of AVP
neurons changes between birth and weaning [44], it would be
interesting to determine whether DLK1 is involved in the post-
natal plasticity of AVP neurons.
We observed that variations in hypothalamic Dlk1 expression
between the early post-natal period and adulthood in mice
correlate negatively with global variations in the expression of the
Notch target gene Hes5 and the Notch ligand Jagged2 (see table
Figure 5. DLK1 expression in AVP and OXT neurons in the PVN,
the SCN and the SON. Dual immunofluorescence staining of DLK1
(antibody C-19) and AVP or OXT on 0.6 mm-thick confocal PVN (A), SCN
(B) and SON (C) sections obtained using a 636objective. Arrowheads
indicate double staining. Scale bars: 10 mm.
doi:10.1371/journal.pone.0036134.g005
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and dendrite growth and synaptic plasticity [45–47], further work
is necessary to determine whether DLK1 could play a role in the
post-natal maturation of hypothalamic neurons via the Notch
pathway as described for adipocyte differentiation [48–50]. A
trans effect of DLK1 on the Notch pathway was proposed [3,51]
as well as a cis-inhibitory effect which was more pronounced with
the uncleaved form than with the cleaved form [49]. However,
due to the absence of valuable antibodies against Notch pathway
actors for IHC, we were unable to determine whether DLK1
could acts in cis or in trans with the Notch pathway in the
hypothalamus. An effect of DLK1 on hypothalamic neurons via
integrin signalling and SOX9 upregulation may be another
hypothesis [52].
Very recently, Ferron et al described a role for Dlk1 in
neurogenesis within the sub-ventricular zone initiating early in
postnatal life [53]. They showed that DLK1 maintains the
potential of cell renewal from a pool of neural stem cells in
coordination with niche astrocytes. The hypothalamus is also the
place of an active neurogenesis in adulthood starting early in
postnatal life [54] and having a potential role in energy balance
[55]. Although, DLK1 staining in the hypothalamus looks broader
than the staining observed with a cell-proliferation marker [55], it
will be interesting to test whether DLK1 is involved in the
regulation of the postnatal neurogenesis in the hypothalamus.
In summary, the data presented here show marked hypotha-
lamic expression of DLK1 in the ARC, DMN, PVN, SON, SCN,
and LH nuclei. DLK1 is expressed in arginine-vasopressin and in
oxytocin expressing neurons but also in neurons that remain to be
characterized in the ARC and DMN. Dlk1 hypothalamic
expression increases between birth and adulthood. We propose
that DLK1 may have a dual role in the hypothalamus: it may play
a role in the post-natal hypothalamic maturation of the AVP and
OXT neurons. Further work is necessary to investigate whether
Dlk1 is involved in the differentiation process of hypothalamic
neuronal stem cells.
Supporting Information
Figure S1 Dlk1 pituitary immunostaining. A) Pituitary
immunostaining with antibodies to DLK1 (C-19) and
growth hormone (GH). A confocal 0.6 mm-thick section
obtained with a 636 objective. Primary antibody used for GH
staining is the polyclonal guinea pig anti rat growth hormone
(NIDDK, Torrance, CA). Arrow heads indicate double staining.
B) DLK1 is not expressed in the neuronal lobe of the
pituitary. Dual immunofluorescence staining on a single 0.6 mm-
thick confocal section obtained using a 406objective. Scale bars,
10 mm; AP: anterior pituitary; NL: neuronal lobe of the pituitary.
(TIF)
Figure S2 Hypothalamic nuclei expressing DLK1 do not
change with age in male mice. Immunostaining with the C-
19 antibody was performed on free-floating sections at P6, P20,
and P60 as described in the ‘‘materials and methods’’ section.
Confocal 0.6 mm-thick sections were obtained with a 406
objective. Suprachiasmatic nucleus (SCN), Paraventricular nucleus
(PVN), lateral hypothalamic nucleus (LH), supraoptic nucleus
(SON), and arcuate nucleus (ARC). Scale bars: 50 mm. The
stained hypothalamic nuclei are the same at the different ages. To
quantify a possible variation of DLK1 expression in each
hypothalamic nucleus at the different stages, RT-qPCR of Dlk1
should be performed on dissected hypothalamic nuclei.
(TIF)
Table S1 PCR primers. Sequences of PCR primers used for
polymerase-chain-reaction amplification (PCR) or quantitative
real-time PCR (qPCR).
(DOC)
Table S2 Hypothalamic mRNA expression of Notch
pathway genes on post-natal days (P) 6, 20 and 60. Total
RNA from pooled hypothalami (n=4) was reverse-transcribed
and analysed using quantitative PCR as described in materials and
methods. The mRNA levels are given relative to GAPDH mRNA
levels. ns: not significant.
(DOC)
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